Patents by Inventor Mark Manfredi

Mark Manfredi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240066040
    Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.
    Type: Application
    Filed: July 19, 2023
    Publication date: February 29, 2024
    Inventors: Mark MANFREDI, Jeffrey Ecsedy, Atsushi Nagahisa, Yukinori Take, Takako Okumura
  • Publication number: 20210353648
    Abstract: The present invention provides grapiprant unit dosage forms, and methods of use thereof for treating a proliferative disorder.
    Type: Application
    Filed: September 27, 2019
    Publication date: November 18, 2021
    Inventors: Mark MANFREDI, Jeffrey ECSEDY, Atsushi NAGAHISA, Takako OKUMURA
  • Publication number: 20210300921
    Abstract: The present invention provides N-((4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzenesulfonamide compositions, and the use thereof for treating a proliferative disorder.
    Type: Application
    Filed: July 11, 2019
    Publication date: September 30, 2021
    Inventors: Mark MANFREDI, Jeffrey ECSEDY, Alfredo C. CASTRO, Yoshiyuki OKUMURA
  • Publication number: 20210290641
    Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.
    Type: Application
    Filed: March 1, 2021
    Publication date: September 23, 2021
    Inventors: Mark Manfredi, Jeffrey ECSEDY, Atsushi NAGAHISA, Yukinori TAKE, Takako OKUMURA
  • Patent number: 10973834
    Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: April 13, 2021
    Assignees: Arrys Therapeutics, Inc., AskAt Inc.
    Inventors: Mark Manfredi, Jeffrey Ecsedy, Atsushi Nagahisa, Yukinori Take, Takako Okumura
  • Publication number: 20190314390
    Abstract: The present invention provides use of an agent that inhibits EP4 activity and an immuno-oncology agent, or a composition thereof, for treatment of a cancer.
    Type: Application
    Filed: April 16, 2019
    Publication date: October 17, 2019
    Inventors: Mark Manfredi, Jeffrey Ecsedy, Atsushi Nagahisa, Yukinori Take, Takako Okumura
  • Patent number: 10391100
    Abstract: The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: August 27, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Mark Manfredi
  • Publication number: 20170296551
    Abstract: The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
    Type: Application
    Filed: December 22, 2016
    Publication date: October 19, 2017
    Inventor: Mark Manfredi
  • Publication number: 20160271249
    Abstract: The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
    Type: Application
    Filed: February 25, 2016
    Publication date: September 22, 2016
    Inventor: Mark Manfredi
  • Publication number: 20100183601
    Abstract: The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.
    Type: Application
    Filed: December 15, 2009
    Publication date: July 22, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Mark Manfredi
  • Publication number: 20080108691
    Abstract: There are provided nuclear hormone receptor modulating compounds of formula I wherein R1, R2, R3, X, Y, n and G are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds. Other embodiments are also disclosed.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 8, 2008
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Lawrence Hamann, David Augeri, Mark Manfredi
  • Publication number: 20070093509
    Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
    Type: Application
    Filed: October 25, 2006
    Publication date: April 26, 2007
    Inventors: William Washburn, Mark Manfredi, Jeffrey Robi, Andres Hernandez
  • Publication number: 20050187267
    Abstract: Compounds are provided which are useful in the treatment of androgen receptor-associated conditions, such as age-related diseases, which compounds have the structure wherein R1 is hydrogen (H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, arylalkyl or substituted arylalkyl, CO2R4a, CONR4aR4b, and CH2OR4a; R2 is hydrogen (H), OR3, SR3, halo, NHR3, NHCOR4c1, NHCO2R4c1, NHCONR4cR4d and NHSO2R4c; R3 in each functional group is hydrogen (H), alkyl or substituted alkyl, CHF2, CF3 and CON4e; R4, R4a, R4b, R4c, R4c1, R4d, R4e, R4f, R4g, or R4h in each functional group are the same or different and are hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, cycloalkyl or substituted cycloalkyl, arylalkyl or substituted arylalkyl, aryl or substituted aryl, or heteroaryl or substituted heteroaryl; R5 and R5? are the same or different and are hydrogen(H), alkyl or substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, c
    Type: Application
    Filed: February 1, 2005
    Publication date: August 25, 2005
    Inventors: Lawrence Hamann, Yingzhi Bi, Mark Manfredi, Alexandra Nirschl, James Sutton
  • Publication number: 20050153968
    Abstract: The present invention relates to novel compounds useful in the treatment of androgen receptor associated conditions, such as age-related diseases, pharmaceutical compositions containing at least one of the compounds of the present invention and methods of treating a patient in need of therapy for an androgen receptor associated condition by administering a therapeutically effective amount of at least compound of the present invention.
    Type: Application
    Filed: November 9, 2004
    Publication date: July 14, 2005
    Inventors: Yingzhi Bi, Lawrence Hamann, Mark Manfredi, Ligaya Simpkins
  • Publication number: 20050059652
    Abstract: The invention provides for a pharmaceutical composition capable of modulating the androgen receptor comprising a compound of formula I wherein R1, R2, R3, X, Y, Z and G are as described herein. Further provided are methods of using such compounds for the treatment of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia, and also provided are pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: November 13, 2003
    Publication date: March 17, 2005
    Inventors: Lawrence Hamann, David Augeri, Mark Manfredi